Zomato founder Deepinder Goyal is exploring neurotech with a prototype wearable that tracks cerebral blood flow in real time. Hinted to be part of a potential venture named Temple, the device taps into biomarkers linked to ageing, cognition, and longevity, signalling Goyal’s move into advanced wellness and brain-health technology.
Deepinder Goyal, the founder of Zomato, has long been associated with transforming how India eats. But now, he appears to be stepping into a very different arena—one that sits at the intersection of health technology, brain science, and the booming global longevity movement. His new experiment, a wearable device that measures cerebral blood flow in real time, has triggered intense curiosity across the tech community, especially after early hints suggested a potential venture under the name Temple. Though official details remain sparse, the buzz around the prototype reveals an ambitious attempt to decode how the brain functions, ages, and adapts in everyday life, using a metric once confined to advanced neurological laboratories.
In a recent social media post, Goyal shared that the device is worn near the temple area of the head and offers live tracking of cerebral blood flow—a biomarker that neuroscience researchers have increasingly associated with cognitive health, memory function, mental clarity, and even the early signs of age-related decline. By focusing on blood flow rather than the more commonly tracked markers like heart rate, steps, or sleep cycles, the prototype moves into largely uncharted territory for consumer wearables. It hints at a future where everyday users could potentially monitor how their brain responds to stress, work, nutrition, meditation, or even ageing itself.
Cerebral blood flow is not a new field of study. Neurologists have long used sophisticated imaging tools such as fMRI and PET scans to understand how blood distribution in the brain correlates with cognitive tasks, emotional states, or neurological disorders. But these technologies are bulky, expensive, and impossible to integrate into daily life. The idea of shrinking this capability into a lightweight wearable—one that sits unobtrusively on the temples—suggests a leap in both hardware innovation and applied neuroscience. For a country like India, where preventive healthcare awareness is still growing and the longevity industry is only beginning to take shape, such a device could accelerate conversations around brain health in profound ways.
Goyal’s foray into longevity technology also aligns with a larger global shift. In Silicon Valley and across Asian tech hubs, the focus on lifespan and healthspan—living longer and living well—has moved from niche interest to mainstream obsession. Wearables that track sleep, heart rate variability, stress, glucose levels and metabolic patterns have become widely used tools for self-quantification. But the brain, arguably the most important organ defining human functioning and identity, has been the least understood and least measured in real time. A consumer-grade device that monitors cerebral blood flow would therefore occupy a groundbreaking position in the wearables market.
What sets Temple, if that indeed becomes the venture’s official name, apart is its potential to democratise brain data. While the prototype is still being tested and no commercial roadmap has been announced, the very act of publicising it indicates Goyal’s intention to expand beyond curiosity into a new business vertical. Industry observers see it as a natural evolution for a founder who has repeatedly explored problems extending far beyond food delivery—whether through health-driven products, fitness partnerships, or technology-led behavioural insights. With Temple, he appears ready to push this curiosity further into the biological realm.
The implications of real-time cerebral blood-flow tracking could be wide-ranging. For professionals dealing with high-stress jobs, fluctuating blood flow could reveal periods of mental fatigue or cognitive overload before they manifest as burnout. For athletes, it might help determine how the brain responds to intense training sessions or recovery routines. For older adults, such a device could offer early warning signs of declining cognitive function, prompting timely medical evaluation. Even students preparing for exams or creators navigating long hours of ideation might use the feedback to understand their optimal cognitive windows. Whether these possibilities materialise will depend on how the technology evolves, what kind of data accuracy it can ensure, and how users choose to interpret and act on the information.
A major factor that could determine Temple’s success is the broader conversation about personal data and privacy. Brain data, unlike steps or calories, is deeply intimate. It can reveal behavioural patterns that users may not even be consciously aware of. Any venture dealing with such information will have to build trust at multiple levels—scientific accuracy, ethical handling of data, and transparent usage mechanisms. In India, where data protection laws are still evolving, companies working in the bio-tracking space must navigate an environment that demands both innovation and caution. Goyal’s reputation as a founder who has built large-scale consumer platforms may help in establishing early credibility, but the challenges in creating a safe, ethically grounded neurotech product are substantial.
On the scientific front, translating something as complex as cerebral blood flow into a metric that ordinary users can understand poses its own difficulties. The brain is affected by countless external and internal factors: hydration levels, emotional states, physical posture, sleep quality, medication, and even breathing patterns. For any wearable to be meaningful, it must not only measure but contextualise this data in ways that lead to actionable insights. If Temple can manage to bridge this gap—offering clear explanations, patterns, or recommendations—it could significantly expand public engagement with brain health.
Another question is affordability. Most advanced neurotech devices today are priced far beyond the reach of regular consumers, making them viable only for research institutions or elite biohackers. Goyal’s ventures, historically, have leaned toward massive consumer adoption. If Temple adopts the same philosophy and aims for a broad market rather than an elite niche, it could mark a transformative step in bringing brain-tech to the mainstream. India, with its vast young population and increasing appetite for wellness tools, could become a powerful testbed for such a product.
What makes this moment particularly striking is that Goyal is experimenting with this technology in a personal capacity, sharing his own early experiences. It signals an approach where the founder becomes the first user, testing functionality, comfort, and usefulness before involving a wider audience. His willingness to publicly mention the prototype suggests confidence in its direction, even if the technology is still in infancy. It also taps into a growing cultural trend where tech leaders often serve as public-facing evangelists for the very products they develop—creating curiosity before commercialisation.
If Temple progresses into a full-fledged venture, it could introduce a new category within India’s startup ecosystem. While the country has seen rapid growth in health-tech, fintech, and consumer services, deep-tech neurotechnology remains nascent. A high-profile entry into this space could not only attract investments but also inspire more founders and researchers to explore the cognitive wellness category. Universities, neuroscience labs, and engineering institutes might find new opportunities to collaborate on such emerging technologies, accelerating innovation within the sector.
Though still evolving, Goyal’s experiment highlights a shift in how future consumer technology might be shaped—not just around convenience and lifestyle, but around deeper metrics of human functioning. The idea that one could monitor cerebral blood flow during a stressful meeting, a meditative session, or a creative brainstorm might change how individuals understand their own mental states. If the prototype eventually becomes accessible and reliable, it could redefine personal wellness in ways that go far beyond traditional fitness tracking.
For now, Temple remains a concept surrounded by curiosity, speculation, and early excitement. But it underscores the expanding ambitions of Indian founders who are increasingly venturing into fields once dominated by Western research labs and deep-tech startups. Whether it becomes a commercially viable product or remains an exploratory project, it reflects a growing aspiration to bring advanced human biomarkers into everyday life. And in that sense, Goyal’s brain wearable marks not just an experiment in technology, but an invitation to imagine what the next decade of wellness could look like—one where understanding the brain becomes as routine as checking one’s pulse.
Discover more from Creative Brands
Subscribe to get the latest posts sent to your email.
